Search clinical trials for: andexanet alfa

Total 3061 results

Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Anemia
Stanford University
National Institute on Aging (NIA)

Withdrawn

Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia

Anemia

United States
University Medical Center Groningen
Janssen-Cilag Ltd.; The Interuniversity Cardiology Institute of the Netherlands

Completed

Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction (HEBEIII)

Myocardial Infarction

Netherlands
Denali Therapeutics Inc.

Recruiting

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) (COMPASS)

Mucopolysaccharidosis II

United States, Spain, United Kingdom, Czechia, France, Canada, Italy, Belgium, Netherlands, Germany, Argentina, Sweden, Turkey, Colombia, Brazil
National Cancer Institute (NCI)

Active, not recruiting

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

Olfactory Neuroblastoma | Esthesioneuroblastoma | Neoplasm of the Nasal Cavity

United States
Sanofi

Approved for marketing

Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD)

Sphingomyelin Lipidosis
AryoGen Pharmed Co.

Completed

Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Iran, Islamic Republic of
Ari Zimran
Pfizer

Active, not recruiting

A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease

Gaucher Disease, Type 3

Israel, Turkey, India
Shire

Completed

Replagal Enzyme Replacement Therapy for Children With Fabry Disease

Fabry Disease

Canada, United States
Shire

Completed

Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

Fabry Disease

United States, United Kingdom, Australia, Czechia, Finland, Paraguay, Poland, Slovenia
Novo Nordisk A/S

Completed

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage (FAST)

Acquired Bleeding Disorder | Intracerebral Haemorrhage

United States, Spain, Germany, Sweden, Netherlands, Austria, Belgium, Singapore, Taiwan, Israel, Italy, Denmark, Australia, Thailand, France, Norway, Croatia, Hong Kong, China, Canada, Switzerland, Brazil, Finland
Baylor Research Institute
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Dosing Study of Replagal in Patients With Fabry Disease

Fabry Disease

United States
Genzyme, a Sanofi Company

Completed

Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies

Glycogen Storage Disease Type II | Pompe Disease Infantile-Onset

United States, France, South Africa
Genzyme, a Sanofi Company

Approved for marketing

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease

Glycogen Storage Disease Type II | Glycogenosis 2
Zydus Lifesciences Limited

Completed

Desidustat in the Treatment of Anemia in CKD (DREAM-ND)

Anemia | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4

India
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) Therapy

Acquired Immunodeficiency Syndrome | Anemia
Federico II University

Completed

Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia

Friedreich's Ataxia

Italy
Ortho Pharmaceuticals

Completed

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

HIV Infections | Cytopenias

United States
Xiamen Amoytop Biotech Co., Ltd.
Peking University People's Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (PEGIFN)

Chronic Hepatitis C

China
Biocad

Completed

An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Hepatitis | Hepatitis C | Hepatitis C/ Human Immunodeficiency Virus Coinfection

Russian Federation
AM-Pharma
FGK Clinical Research GmbH

Recruiting

Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery

Open Heart Surgery

Germany
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa (CHESTNUT)

Hypophosphatasia

Australia, United States, Japan, Germany, Turkey, Italy, India, France, United Kingdom, Argentina, Canada
Alexion

Recruiting

A Prospective Sub-Study of the Global Hypophosphatasia Registry

Hypophosphatasia

United States
The University of Hong Kong

Recruiting

Ropeginterferon Alfa 2b for Early Myelofibrosis

Myelofibrosis | Primary Myelofibrosis, Prefibrotic Stage

Hong Kong
Sanofi

Recruiting

Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa (Baby-COMET)

Glycogen Storage Disease Type II

Belgium, United States, China, Germany, Italy, Netherlands, Spain, Taiwan, United Kingdom
Takeda

Active, not recruiting

A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

Gaucher Disease

China
Amgen

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Poland, Germany, France
UNICANCER
Merck KGaA, Darmstadt, Germany

Terminated

Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma (ICING)

Squamous Cell Carcinoma of Head and Neck

France
Organon and Co

Completed

A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)

Infertility, Female
Shire

Completed

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

Fabry Disease

Canada
Shire

No longer available

Treatment Protocol of Replagal for Patients With Fabry Disease

Fabry Disease

United States
Shaare Zedek Medical Center

Completed

Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease

Primary Disease

Israel
LMU Klinikum
Genzyme, a Sanofi Company

Completed

Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study) (STIG)

Pompe Disease

Germany, Taiwan, Italy
Baylor Research Institute
Texas Scottish Rite Hospital for Children

Withdrawn

The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

Gaucher Disease Type 1 | Gaucher Disease Type 3

United States
Pfizer

Completed

Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B

Hemophilia B

Canada, Singapore, Turkey, Croatia, Korea, Republic of, Mexico, Poland, Bulgaria, Malaysia
Shin Kong Wu Ho-Su Memorial Hospital

Unknown

Corifollitropin Alfa Application in PCOS Patients

In Vitro Fertilization

Taiwan
Genzyme, a Sanofi Company

Completed

Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602

Glycogen Storage Disease Type II

United States, France, Germany, Israel, Italy, Netherlands, Taiwan
Genzyme, a Sanofi Company

Completed

A Study of rhGAA in Patients With Late-Onset Pompe Disease

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2

Netherlands
Genzyme, a Sanofi Company

Completed

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease

Glycogen Storage Disease Type II | Glycogenosis 2

United States
Genzyme, a Sanofi Company

Completed

Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.

Pompe Disease Late-Onset | Glycogen Storage Disease Type II GSD II

United States
Genzyme, a Sanofi Company

Completed

Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2

France
Chiesi Farmaceutici S.p.A.

Not yet recruiting

Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3 (LAMPO(0-3))

Alpha-Mannosidosis
Novo Nordisk A/S

Completed

A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States
David L Rogers, MD

Active, not recruiting

Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2

Neuronal Ceroid Lipofuscinosis Type 2

United States
Pfizer

Completed

Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B

Hemophilia B

India
Genzyme, a Sanofi Company

Completed

Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment (APOLLO-IOPD)

Glycogen Storage Disease Type II

China
Genzyme, a Sanofi Company

Completed

Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease (PAPAYA)

Pompe Disease | Glycogen Storage Disease Type II (GSD II)

United States, Russian Federation, United Kingdom, Bulgaria, India, Ukraine
Shire

Completed

This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.

Fabry Disease

Canada
Shire
Quintiles, Inc.

Completed

Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease

Gaucher Disease

Japan
Chiesi Farmaceutici S.p.A.

Withdrawn

Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis (SHAMAN)

Alpha-Mannosidosis

3

Subscribe